ARK Genomic Revolution ETF vs Quantum Computing Inc — how do they compare? ARK Genomic Revolution ETF trades at $44.61, while Quantum Computing Inc trades at $8.9 (market cap $2.03B). The key difference: ARK Genomic Revolution ETF is trading nearer its 52-week high, Quantum Computing Inc nearer its low. Which is the better fit depends on your goals.
| ARKG | QUBT | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $44.55 | $24.62 |
52-Week Low | $24.02 | $6.31 |
Market Cap | — | $2.03B |
Enterprise Value | — | $1.09B |
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $44.69 with a 0.86% daily gain, showing bullish momentum with strong moving average signals but overbought oscillators. The ETF focuses on genomic revolution companies with 59% concentration in top 10 holdings and long-term EPS growth of 10.7%. Recent news highlights biotech sector strength and ARKG's recovery from July correction.
Outlook remains positive given biotech sector tailwinds including FDA friendliness and AI-driven drug discovery, though high RSI readings suggest near-term caution. Key risks include sector volatility and concentrated portfolio exposure.
Quantum Computing Inc. (QUBT) trades at $8.92, down slightly by 0.11% on the day, with a bearish technical signal. The company is in a high-growth but pre-profit phase, reporting Q2 2026 revenue of $5.6 million (MarketBeat, 2026-08-10), a significant increase, but with persistent net losses. Analyst sentiment is positive with a 75% buy rating and a consensus price target of $18.50, indicating substantial upside potential from current levels.
The outlook for QUBT is speculative, offering high growth potential in quantum computing and photonics, supported by strong institutional interest and revenue expansion. Key risks include steep valuation (P/S of 189.05), ongoing losses, high cash burn, and competitive pressures in the emerging quantum sector, requiring careful risk assessment by investors.
Trailing returns across standard periods
Latest headlines on both assets
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →Quantum Computing Inc. is a company focused on providing accessible quantum computing and quantum-enhanced software solutions for complex problems. The company's technology is designed to run on both classical and quantum hardware, enabling businesses to explore the power of quantum computing today for applications in finance, drug discovery, and logistics. QUBT offers a platform that makes quantum algorithms and software available through the cloud, aiming to democratize access to this advanced computing paradigm.
Read more on QUBT →